Krista Davis Sells 1,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Krista Davis also recently made the following trade(s):

• On Friday, February 21st, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $60.20, for a total value of $60,200.00.
• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.00, for a total value of $60,000.00.

ANI Pharmaceuticals Stock Performance

ANIP stock traded down $1.80 during midday trading on Thursday, reaching $61.46. The company had a trading volume of 145,816 shares, compared to its average volume of 242,315. The firm has a market capitalization of $1.34 billion, a PE ratio of -111.75 and a beta of 0.62. The stock has a 50 day moving average price of $58.14 and a 200 day moving average price of $58.11. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE lifted its stake in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after purchasing an additional 579 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Finally, HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $222,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ANIP. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price for the company. Guggenheim increased their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. Finally, StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $79.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.